Boehringer Ingelheim: Neoplasms trials
The registry lists 61 Neoplasms studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 41 have results posted.
Early Phase 1 1Phase 1 55Phase 2 3No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have SpreadCompletedNCT04147247Phase 1Results posted
- A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)CompletedNCT04147234Phase 1Results posted
- A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)CompletedNCT04138823Phase 1Results posted
- A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced CancerCompletedNCT03972150Phase 1Results posted
- This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)TerminatedNCT03604445Phase 1Results posted
- A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid TumoursCompletedNCT03468426Phase 1Results posted
- This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of CancerCompletedNCT03433898Early Phase 1Results posted
- A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have SpreadTerminatedNCT03166631Phase 1Results posted
- This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.CompletedNCT03156114Phase 1Results posted
- This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerCompletedNCT03099174Phase 1Results posted
- A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid TumoursCompletedNCT02952248Phase 1Results posted
- Weekly BI 836880 in Patients With Advanced Solid TumorsCompletedNCT02689505Phase 1Results posted
- Dose Finding Study of BI 836880 in Patients With Solid TumorsCompletedNCT02674152Phase 1Results posted
- BI 894999 First in Human Dose Finding Study in Advanced MalignanciesCompletedNCT02516553Phase 1Results posted
- BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid TumoursCompletedNCT02273388Phase 1Results posted
- Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid TumoursCompletedNCT02145741Phase 1Results posted
- BI 836845 in Estrogen Receptor Positive Metastatic Breast CancerCompletedNCT02123823Phase 1Results posted
- Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid TumoursCompletedNCT02020577Phase 1Results posted
- Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is KnownCompletedNCT01971476Phase 1Results posted
- BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid TumorsCompletedNCT01938846Phase 1Results posted
- Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various TumoursCompletedNCT01772563Phase 1Results posted
- Phase I Trial of BI 836845 for Various Solid CancerCompletedNCT01403974Phase 1Results posted
- BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid TumoursCompletedNCT01348347Phase 1Results posted
- Monotherapy Dose Finding With BI 847325 in Solid TumoursCompletedNCT01324830Phase 1Results posted
- Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour TypesCompletedNCT01317420Phase 1Results posted
- A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus DocetaxelCompletedNCT01251653Results posted
- BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid TumoursCompletedNCT01214616Phase 1Results posted
- An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid TumoursCompletedNCT01206816Phase 1Results posted
- BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid TumoursCompletedNCT01169675Phase 1Results posted
- BI 6727 (Volasertib) Human ADME Trial in Various Solid TumoursCompletedNCT01145885Phase 1Results posted
- Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial CancerCompletedNCT01023958Phase 2Results posted
- Combination of BI6727 (Volasertib) and BIBF1120 in Solid TumorsCompletedNCT01022853Phase 1Results posted
- Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.CompletedNCT00998296Phase 1Results posted
- BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid TumourCompletedNCT00969761Phase 1Results posted
- Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid CancersCompletedNCT00969553Phase 1Results posted
- Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2CompletedNCT00906698Phase 1Results posted
- Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid TumoursCompletedNCT00875433Phase 2Results posted
- Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid TumoursCompletedNCT00809133Phase 1Results posted
- Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.TerminatedNCT00748709Phase 2Results posted
- Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid TumoursCompletedNCT00716417Phase 1Results posted
- A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120CompletedNCT00715403Phase 1Results posted
- A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerActive, not recruitingNCT04958239Phase 1
- A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)CompletedNCT03964233Phase 1
- This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)CompletedNCT03449381Phase 1
- The Use of Angiotensin Receptor Blockers and the Risk of CancerCompletedNCT02215733
- BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical BenefitCompletedNCT02211872Phase 1
- Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical BenefitCompletedNCT02211859Phase 1
- An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid TumoursCompletedNCT02182206Phase 1
- A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid TumoursCompletedNCT02182128Phase 1
- Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171741Phase 1
- Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171728Phase 1
- Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumoursCompletedNCT02171702Phase 1
- BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171676Phase 1
- Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171663Phase 1
- BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171650Phase 1
- Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171637Phase 1
- A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic CancerCompletedNCT01905111Phase 1
- A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic CancerCompletedNCT01335269Phase 1
- Phase I Study of BI 831266 in Patients With Advanced Solid TumoursCompletedNCT00756223Phase 1
- Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid TumorsCompletedNCT00730821Phase 1
- BI 811283 in Various Solid TumoursCompletedNCT00701324Phase 1